305
Participants
Start Date
January 8, 2014
Primary Completion Date
October 17, 2016
Study Completion Date
January 8, 2019
Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody
Atezolizumab will be administered according to the dosage schedule mentioned in the arm description.
Bevacizumab
Bevacizumab will be administered according to the dosage schedule mentioned in the arm description.
Sunitinib
Sunitinib will be administered according to the dosage schedule mentioned in the arm description.
Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milan
Hosp de Madrid Norte Sanchinarro; Centro Integral; Onco Clara Campal, Madrid
Medizinische Hochschule; Zentrum Innere Medizin; Abt. Hämatologie u. Onkologie, Hanover
Clinica Universitaria de Navarra, Pamplona
Mayo Clinic-Jacksonville, Jacksonville
CHU Bordeaux, Pessac
Florida Cancer Specialist, North Region, St. Petersburg
SCRI Florida Cancer Specialists South, Fort Myers
Tennessee Oncology PLLC - Nashville (20th Ave), Nashville
Cleveland Clinic Foundation; Taussig Cancer Center, Cleveland
Oncology Hematology Care Inc, Cincinnati
Karmanos Cancer Institute., Detroit
Medical Oncology, Arezzo, Arezzo
Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica, Siena
The University of Chicago, Chicago
Texas Oncology-Baylor Sammons Cancer Center, Dallas
Hopital Europeen Georges Pompidou; Service D'Oncologie Medicale, Paris
Univ Colorado Health Sci Ctr, Aurora
Rocky Mountain Cancer Ctr - Denver (Williams), Denver
Klinikum d.Universität München Campus Großhadern, München
Klinikum rechts der Isar der TU München; Klinikapotheke, München
HonorHealth Research Institute - Bisgrove, Scottsdale
Comprehensive Cancer Centers of Nevada, Las Vegas
UCLA, Los Angeles
City of Hope Comprehensive Cancer Center, Duarte
University of California, San Francisco
Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif
Northwest Cancer Specialists, P.C., Tigard
Oncology Associates of Oregon, P.C, Eugene
Prof. Dr. I. Chiricuta Institute of Oncology, Cluj-Napoca
Medisprof SRL, Cluj-Napoca
Yale Uni School of Medicine; Section of Medical Oncology, New Haven
Georgetown U; Lombardi Comp Can, Washington D.C.
Massachusetts General Hospital, Boston
Dana Farber Cancer Inst., Boston
Beth Israel Deaconess Medical Center, Boston
Memorial Sloan-Kettering, New York
Vanderbilt Medical Center, Nashville
Fakultni nemocnice Olomouc, Olomouc
Centrum Med. Ostrobramska NZOZ Magodent, Warsaw
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Clinic de Barcelona. Unidad de Nuevas Terapias;Oncology Department, Barcelona
Barts and the London NHS Trust., London
Royal Marsden Hospital - London, London
Christie Hospital Nhs Trust; Medical Oncology, Manchester
Hoffmann-La Roche
INDUSTRY